Global burden of liver disease: 2023 update

Journal of Hepatology, Journal Year: 2023, Volume and Issue: 79(2), P. 516 - 537

Published: March 27, 2023

Liver disease accounts for two million deaths annually and is responsible 4% of all (1 out every 25 worldwide); approximately two-thirds liver-related occur in men. Deaths are largely attributable to complications cirrhosis hepatocellular carcinoma, with acute hepatitis accounting a smaller proportion deaths. The most common causes worldwide related viral hepatitis, alcohol, non-alcoholic fatty liver disease. Hepatotropic viruses the aetiological factor cases but drug-induced injury increasingly significant cases. This iteration global burden an update 2019 version focuses mainly on areas where new information available like alcohol-associated disease, carcinoma. We also devote separate section Africa, area world typically neglected such documents.

Language: Английский

---

Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians

CA A Cancer Journal for Clinicians, Journal Year: 2022, Volume and Issue: 73(2), P. 198 - 222

Published: Oct. 19, 2022

Abstract Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver tumor and remains a fatal malignancy in majority of patients. Approximately 20%–30% patients are eligible for resection, which considered only potentially curative treatment; and, after median survival 53 months has been reported when sequenced with adjuvant capecitabine. For 70%–80% who present locally unresectable or distant metastatic disease, systemic therapy may delay progression, but limited to approximately 1 year. past decade, doublet chemotherapy gemcitabine cisplatin effective first‐line regimen, results from recent use triplet regimens even immunotherapy shift paradigm. More treatment strategies, including those that combine locoregional therapies like radioembolization hepatic artery infusion, have also developed. Molecular therapies, target fibroblast growth factor receptor isocitrate dehydrogenase, recently received US Food Drug Administration approval defined role as second‐line up 40% harboring these actionable genomic alterations, whether they should be setting under investigation. Furthermore, oncology field seeks expand indications immunotherapy, data demonstrated combining durvalumab standard cytotoxic improved ICC. This review focuses on current future strategies ICC treatment, summary literature each modality an algorithm can used drive personalized multidisciplinary approach this challenging malignancy.

Language: Английский

---

Current epidemiology of cholangiocarcinoma in Western countries

Journal of Hepatology, Journal Year: 2022, Volume and Issue: 77(6), P. 1690 - 1698

Published: Aug. 14, 2022

Language: Английский

---

Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma

Journal of Hepatology, Journal Year: 2023, Volume and Issue: 79(1), P. 93 - 108

Published: March 1, 2023

Language: Английский

---

Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma

Journal of Hepatology, Journal Year: 2022, Volume and Issue: 78(3), P. 614 - 626

Published: Dec. 15, 2022

In recent years, intrahepatic cholangiocarcinoma (iCCA) has evolved as a "role model" for precision oncology in gastrointestinal cancers. However, its rarity, paired with genomic heterogeneity, challenges the development and evolution of targeted therapies. Interrogating large datasets drives better understanding characteristics molecular subgroups rare cancers enables identification patterns that remain unrecognized smaller cohorts.We performed retrospective analysis 6,130 patients diagnosed iCCA from FoundationCORE database who received diagnostic panel sequencing on FoundationOne platform. Short variants/fusion-rearrangements copy number alterations >300 tumor-associated genes were evaluated, tumor mutational burden (TMB) well microsatellite instability (MSI) status available majority cohort.We provide highly representative cartography landscape outline co-mutational spectra seven therapeutically relevant oncogenic driver genes: IDH1/2, FGFR2, ERBB2, BRAF, MDM2, BRCA1/2, MET KRASG12C. We observed negative selection RTK/RAS/ERK pathway co-alterations, an enrichment epigenetic modifiers such ARID1A BAP1 IDH1/2 FGFR2 alterations. RNF43 KMT2D occurred high frequency MSIhigh TMBhigh tumors.Detailed knowledge most prevalent constellations is key to effective treatment strategies iCCA. Our study provides valuable resource could be used assess feasibility clinical trials subgroup analyses, spurs translationally preclinical models, serves base predict potential mechanisms resistance therapies genomically defined subgroups.Due targetable alterations, diagnostics recommended biliary tract cancers, especially those The actionable lesion, however, does not guarantee therapeutic success, spectrum may act critical modifier drug response. Using dataset comprehensive results iCCA, we detailed frequent druggable genetic which meant serve reference establish genetically develop hypothesis-driven combination identify recurrent profiles.

Language: Английский

---

Immunology and immunotherapy of cholangiocarcinoma

Nature Reviews Gastroenterology & Hepatology, Journal Year: 2023, Volume and Issue: 20(6), P. 349 - 365

Published: Jan. 25, 2023

Language: Английский

---

Liquid biopsy in cancer current: status, challenges and future prospects

Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)

Published: Dec. 1, 2024

Cancer has a high mortality rate across the globe, and tissue biopsy remains gold standard for tumor diagnosis due to its level of laboratory standardization, good consistency results, relatively stable samples, accuracy results. However, there are still many limitations drawbacks in application tumor. The emergence liquid provides new ideas early prognosis Compared with biopsy, advantages treatment various types cancer, including non-invasive, quickly so on. Currently, detection received widely attention. It is now undergoing rapid progress, it holds significant potential future applications. Around now, biopsies encompass several components such as circulating cells, DNA, exosomes, microRNA, RNA, platelets, endothelial cells. In addition, advances identification indicators have significantly enhanced possibility utilizing clinical settings. this review, we will discuss application, challenges some common tumors from perspective diverse systems tumors, look forward development prospects field cancer treatment.

Language: Английский

---

Inequities in primary liver cancer in Europe: The state of play

Journal of Hepatology, Journal Year: 2024, Volume and Issue: 80(4), P. 645 - 660

Published: Jan. 17, 2024

Language: Английский

---

Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial

˜The œLancet. Gastroenterology & hepatology, Journal Year: 2024, Volume and Issue: 9(8), P. 734 - 744

Published: June 13, 2024

Language: Английский

---

An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202

ESMO Open, Journal Year: 2024, Volume and Issue: 9(6), P. 103488 - 103488

Published: June 1, 2024

•FIGHT-202 evaluated pemigatinib in patients with previously treated, advanced/metastatic CCA FGFR2 rearrangements.•Median follow-up was 45.4 months; demonstrated an ORR of 37% and a median DOR 9.1 months.•Median PFS OS were 7.0 17.5 months, respectively.•AEs treatment manageable; during extended follow-up, no new safety signals identified.•The importance tumor molecular profiling efficacy fusions/rearrangements are described. BackgroundFibroblast growth factor receptor 2 (FGFR2) fusions rearrangements clinically actionable genomic alterations cholangiocarcinoma (CCA). Pemigatinib is selective, potent, oral inhibitor FGFR1-3 FIGHT-202 (NCT02924376). We report final outcomes from the period.Patients methodsThe multicenter, open-label, single-arm, phase II study enrolled ≥18 years old treated or (cohort A), other FGF/FGFR B), C). Patients received once-daily 13.5 mg 21-day cycles (2 weeks on, 1 week off) until disease progression unacceptable toxicity. The primary endpoint objective response rate (ORR) cohort A assessed as per RECIST v1.1 by independent review committee; secondary endpoints included duration (DOR), progression-free survival (PFS), overall (OS), safety.ResultsFIGHT-202 147 A, 108; B, 20; C, 17; unconfirmed alterations, 2). By analysis, 145 (98.6%) had discontinued due to progressive (71.4%), withdrawal patient (8.2%), adverse events (AEs; 6.8%). Median months. 37.0% (95% confidence interval 27.9% 46.9%); complete partial responses observed 3 37 patients, respectively. (6.0-14.5) (6.1-10.5) months (14.4-22.9) most common treatment-emergent AEs (TEAEs) hyperphosphatemia (58.5%), alopecia (49.7%), diarrhea (47.6%). Overall, 15 (10.2%) experienced TEAEs leading discontinuation; intestinal obstruction acute kidney injury (n = each) occurred frequently.ConclusionsPemigatinib durable prolonged manageable period FIGHT-202. Fibroblast period. safety. frequently.

Language: Английский

---